Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Athenex, Inc. stock logo
ATNX
Athenex
$0.95
$0.20
$23.80
$1.76M1.36194,316 shs1.88 million shs
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
$0.30
-25.9%
$0.36
$0.30
$1.34
$1.02M1.8289,627 shs753,013 shs
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
$0.07
$0.01
$0.01
$726K1.632.58 million shs2.48 million shs
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
$0.38
$0.38
$0.36
$4.80
$1.43MN/AN/AN/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Athenex, Inc. stock logo
ATNX
Athenex
0.00%0.00%0.00%0.00%0.00%
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
0.00%0.00%0.00%0.00%-75.00%
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Athenex, Inc. stock logo
ATNX
Athenex
0.2112 of 5 stars
0.00.00.04.10.60.00.0
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Athenex, Inc. stock logo
ATNX
Athenex
0.00
N/AN/AN/A
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
0.00
N/AN/AN/A
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
0.00
N/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Athenex, Inc. stock logo
ATNX
Athenex
$102.82M0.00N/AN/A($3.07) per share0.00
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
$320K3.19N/AN/A$4.56 per share0.07
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
$2.59M0.00N/AN/A($0.21) per share0.00
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Athenex, Inc. stock logo
ATNX
Athenex
-$103.43M-$15.88N/AN/AN/A-86.31%-727.79%-44.44%N/A
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
-$4.31MN/A0.00N/AN/AN/AN/AN/AN/A
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
-$44.37M-$0.46N/AN/AN/A-1,593.93%N/A-113.02%N/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
-$4.37MN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Athenex, Inc. stock logo
ATNX
Athenex
N/AN/AN/AN/AN/A
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
N/AN/AN/AN/AN/A
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
N/AN/AN/AN/AN/A
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Athenex, Inc. stock logo
ATNX
Athenex
3.08
1.09
0.72
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
N/A
0.43
N/A
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
N/A
1.65
1.65
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Athenex, Inc. stock logo
ATNX
Athenex
30.48%
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
1.91%
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
22.14%
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
12.37%

Insider Ownership

CompanyInsider Ownership
Athenex, Inc. stock logo
ATNX
Athenex
9.20%
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
13.03%
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
9.81%
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
7.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Athenex, Inc. stock logo
ATNX
Athenex
6528.66 million7.87 millionOptionable
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
203.40 million2.96 millionNot Optionable
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
3090.76 million81.86 millionOptionable
NeuBase Therapeutics, Inc. stock logo
NBSE
NeuBase Therapeutics
403.75 million3.46 millionNot Optionable

Recent News About These Companies

Greenlight Capital Q3 2024 Letter
Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?
NeuBase Therapeutics Inc
NeuBase Therapeutics, Inc. (NBSE)
NeuBase Therapeutics Inc (O7P.BE)
CMU halts licensing agreement with NeuBase Therapeutics
NeuBase Therapeutics Inc NBSE
NeuBase Therapeutics: Other Events
NeuBase Therapeutics, Inc. (NBSE.MX)
Athenex stock logo

Athenex NASDAQ:ATNX

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Altamira Therapeutics stock logo

Altamira Therapeutics NASDAQ:CYTO

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.

Infinity Pharmaceuticals stock logo

Infinity Pharmaceuticals NASDAQ:INFI

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.

NeuBase Therapeutics stock logo

NeuBase Therapeutics NASDAQ:NBSE

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.